Insulin is a primary autoantigen in autoimmune diabetes, and insulin autoantibodies (IAA) are often the earliest detectable markers of disease, particularly during initial immune activation. The presence of IAA reflects loss of immune tolerance to insulin. Signosis has developed a mouse Anti-IAA ELISA kit to quantitatively detect insulin autoantibodies in serum or plasma, supporting early-stage diabetes research and longitudinal monitoring in murine models.